NUVB: IBTROZI and safusidenib drive growth with best-in-class efficacy and expanding global opportunities
IBTROZI leads the ROS1 TKI market with strong efficacy and safety, while safusidenib shows unprecedented results in glioma, positioning it for significant market expansion. Educational efforts and improved testing are driving adoption, and the DDC platform promises future innovation.Based on Nuvati…
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.